A recombinant soluble form of the a subunit of the human high-affinity receptor for IgE (rsFceRla), one of the potent IgE-binding molecules, was tested for its ability to regulate IL-4-induced IgE synthesis by human lymphocytes. Addition of rsFcERIc to cultures induced a dose-dependent inhibition of the T cell-dependent and independent synthesis of IgE. The suppression of IgE synthesis was observed at the protein and the mRNA levels, and it was IgE class specific. By flow cytometry, specific binding of rsFceRlei was detected on surface IgE-bearing B cells as well as on U266 cells, and it was completely blocked by preincubation with IgE. rsFcERIac bound to the cell surface IgE could be effectively dissociated not only by a large excess of IgE, but also by an anti-rsFceRfle mAb that competes with IgE for the binding to rsFceRla. This mAb abolished the rsFcERIamediated suppression of IgE synthesis. These data suggest that rsFceRIa may have a function in selectively suppressing IgE synthesis through its interaction with the membrane-bound form of IgE. (J. Clin. Invest. 1994. 94:2162-2165
Introduction
It is well-documented that IgE-binding factors derived from T cells can selectively modulate the IgE response, possibly by regulating the differentiation of IgE-bearing B cells to IgEproducing cells ( [1] [2] [3] . Although the induction of IgE synthesis is also controlled by several cytokines such as IFN-a, IFN-'y, TGF-3, IL-8, and IL-12 (4-7), IgE-binding factors play an important role in the isotype-specific regulation of the IgE response. The high-affinity receptor for IgE (FceRI) mainly expressed on mast cells and basophils has a tetrameric structure (afPy2), of which the a subunit binds IgE with high affinity.
A recombinant soluble form of the a subunit of human FcERI (rsFceRIa)1 is shown to bind IgE with an affinity as high as that of native FcERI (8) . Moreover, rsFceRIa has the ability to inhibit the IgE-mediated allergic reaction, exclusively by interfering with IgE binding to mast cells and basophils. On the basis of the finding that rsFceRIa is a potent IgE-binding molecule, we examined whether it may regulate the human IgE response in vitro. Here we demonstrate that rsFceRla inhibits IgE synthesis by IL-4-stimulated human lymphocytes and that this suppression is mediated by its specific binding to IgEbearing B cells.
Methods
Reagents. Human rIL-4 was purchased from Genzyme Corp. (Boston, MA). Anti-CD40 mAb (B-B20) was obtained from Serotec Ltd. (Kidlington, Oxford, England). Hydrocortisone (HC) and pokeweed mitogen (PWM) were purchased from Sigma Chemical Co. (St. Louis, MO) . FITC-conjugated anti-human IgE mAb was obtained from Nordic Immunological Laboratories (Tilburg, The Netherlands), and phycoerythrin (PE)-conjugated streptavidin was from Becton Dickinson (Mountain View, CA). Human IgE myeloma protein and U266 cells were the same preparations as previously described (9) .
Human rsFceRIa and mAbs to rsFcERIa. The cDNA encoding the leader peptide and 95% of the human FceRIa exodomain (residue numbers 1-172) was introduced into an eukaryotic expression vector, pcDLSRa (8) . The resulting vector and a vector inserted with dihydrofolate reductase (DHFR) coding sequence were cotransfected into DHFRdeficient CHO cells. Secreted rsFcERIa was purified from the culture supernatant of the cells through mouse IgE-coupled Sepharose columns. Two mouse anti-rsFcERIa mAbs (CRA-1 and -2) were prepared and characterized as described elsewhere (8 (12) , an attempt was made to establish an RIA that displays no inhibition of the IgE measurement by rsFcERIa. To this end, several combinations of antibodies against IgE were tested for the exact measurement of IgE in the presence of rsFccRIa. The best result was obtained when clone 89, which had been obtained from American Type Culture Collection (Rockville, MD), was used to coat the solid phase, and clone 5G.1 1.11.7 (anti-Ccl mAb; Immunotech S. A., Marseille, France) was used as the radioiodinated second antibody. Although the epitope specificity of 89 was not determined in detail, this mAb could not bind to the Fcc epitopes recognized by at least two mAbs against Ccd and CE2.
This preliminary observation indicates that 89 may recognize either the Cr3 (but not IgE-binding site) or CE4 domain. Nevertheless, rsFcERIa at 0.1-1,000 ng/ml, regardless of its concentration, showed -30% inhibition of the RIA. However, no significant differences were observed among these five concentrations of rsFcfRla when the standard curve was constructed by calculating least-square lines. For example, they were log y = 1.23 log x + 2.43 (r = 0.999) in the control vs log y = 1.22 log x + 2.25 (r = 0.998) in 0.1 ng/ml of rsFcERIa and log y = 1.24 log x + 2.25 (r = 0.999) in 1,000 ng/ml of the agent, respectively. To determine IgE levels in the culture supernatants containing rsFcERIa, rsFccRIa at a final concentration of 100 ng/ml was usually added to the control culture supernatant before the assay. IgG, IgM, and IgA concentrations in the culture supernatants were measured by sandwich RIAs exactly as described (10) , and each assay was not affected by adding rsFccRIa at any concentration.
Northern blot analysis of Cc mRNA. Total RNA was extracted from cultured cells by the single step method as previously described (13) . 10 ,sg of total RNA was electrophoresed in 1% agar gel containing 6% formaldehyde, and then transferred onto nylon membrane. The membrane was hybridized with 32P-labeled human Cr probe at 42°C for 12 h. Human ,B-actin control was also performed on the membrane transferred from gels prepared in parallel from the same RNA samples. Membranes were washed, air-dried, and then exposed to Kodak XARfilms ( CD40 mAb or HC. As summarized in Fig. 1 , addition of rsFceRla at 1-100 ng/ml could induce a concentration-dependent inhibition of IgE synthesis by PBMC stimulated with IL-4 as well as by purified B cells costimulated with IL-4 and anti-CD40 mAb or HC, and the suppression of IgE synthesis by rsFcERIa (10 and 100 ng/ml) in three such systems was statistically significant (P < 0.05). This suppression does not result from the inhibition of the IgE assay by rsFcERIa, because IgE levels in the control culture supernatant supplemented with rsFceRIa just before IgE measurement were compared with those in the samples. Since IL-4 is shown to have no ability to induce the production of IgG (except for IgG4), IgM or IgA ( 14), we next studied whether rsFceRIa may affect the production of IgG, IgM, and IgA by PWM-stimulated PBMC. As a result, rsFceRIa at 1-100 ng/ml showed no suppressive effects on the production of these isotypes in three different donors. For example, the amounts of immunoglobulins produced in the absence and presence of 100 ng/ml of rsFcERIa were 2.41+0.20 vs 2.40±0.15 (mean±I SEM) yg/ml for IgG, 1.52+0.48 vs 1.65±0.26 gg/ml for IgM, and 0.67±0.08 vs 0.69±0.10 ,ILg/ml for IgA, respectively. These results indicate that the suppression of immunoglobulin production by rsFcERla is IgE class specific. The IgE-suppressive activity of rsFceRIa was further investigated at the transcriptional level, using purified B cells stimulated with IL-4 alone or with the combination of IL-4 and anti-CD40 mAb. Three independent experiments were performed for each Northern blot analysis, and one representative result is presented in Fig. 2 . rsFcERIa at 10 and 100 ng/ml dose-dependently inhibited the expression of the mature (productive and membrane-bound) CE The observation that rsFceRIa suppressed the T cell-dependent and independent synthesis of IgE prompted us to examine the possibility that B cells may be targets for the action of rsFceRIa. As shown in Fig. 3 
